AstraZeneca Historical Income Statement
| AZN Stock | 10,568 30.00 0.28% |
Historical analysis of AstraZeneca PLC income statement accounts such as Interest Expense of 1.7 B, Total Revenue of 24.2 B or Gross Profit of 19.9 B can show how well AstraZeneca PLC performed in making a profits. Evaluating AstraZeneca PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AstraZeneca PLC's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC is a good buy for the upcoming year.
AstraZeneca |
About AstraZeneca Income Statement Analysis
AstraZeneca PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AstraZeneca PLC shareholders. The income statement also shows AstraZeneca investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
AstraZeneca PLC Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts AstraZeneca PLC generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of AstraZeneca PLC minus its cost of goods sold. It is profit before AstraZeneca PLC operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AstraZeneca PLC. It is also known as AstraZeneca PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from AstraZeneca PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AstraZeneca PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from AstraZeneca PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, AstraZeneca PLC's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 11.5 B, whereas Gross Profit is forecasted to decline to about 19.9 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.3B | 1.3B | 1.6B | 1.7B | Depreciation And Amortization | 4.1B | 5.3B | 4.9B | 5.2B |
AstraZeneca PLC income statement Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.8B | 2.9B | 4.1B | 5.3B | 4.9B | 5.2B | |
| Interest Expense | 1.4B | 1.3B | 1.3B | 1.3B | 1.6B | 1.7B | |
| Total Revenue | 24.4B | 26.6B | 37.4B | 44.4B | 45.8B | 24.2B | |
| Gross Profit | 19.5B | 21.3B | 25.0B | 32.0B | 37.8B | 19.9B | |
| Other Operating Expenses | 21.2B | 21.5B | 36.4B | 40.6B | 37.6B | 19.0B | |
| Operating Income | 2.9B | 5.2B | 1.1B | 3.8B | 8.2B | 5.0B | |
| Ebit | 3.0B | 5.2B | 1.0B | 3.8B | 8.5B | 5.1B | |
| Research Development | 6.0B | 6.0B | 9.7B | 9.8B | 10.9B | 11.5B | |
| Ebitda | 6.7B | 8.1B | 5.1B | 9.1B | 13.4B | 7.3B | |
| Total Operating Expenses | 16.3B | 16.2B | 23.9B | 28.2B | 29.6B | 31.1B | |
| Income Before Tax | 1.5B | 3.9B | (265M) | 2.5B | 6.9B | 4.5B | |
| Total Other Income Expense Net | (1.4B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.2B) | |
| Net Income | 1.3B | 3.2B | 112M | 3.3B | 6.0B | 3.5B | |
| Income Tax Expense | 321M | 772M | (380M) | (792M) | 938M | 729.2M | |
| Selling General Administrative | 11.7B | 11.7B | 95M | 19.0B | 197M | 187.2M | |
| Cost Of Revenue | 4.9B | 5.3B | 12.4B | 12.4B | 8.0B | 6.5B | |
| Net Income Applicable To Common Shares | 1.3B | 3.2B | 112M | 3.3B | 3.0B | 3.2B | |
| Minority Interest | 1.5B | 16M | (3M) | (5M) | (6M) | (5.7M) | |
| Selling And Marketing Expenses | 11.8B | 11.7B | 15.7B | 19.0B | 18.2B | 11.9B | |
| Net Income From Continuing Ops | 1.2B | 3.1B | 115M | 3.3B | 6.0B | 6.3B | |
| Tax Provision | 321M | 772M | (380M) | (792M) | 938M | 984.9M | |
| Net Interest Income | (1.2B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.4B) | |
| Interest Income | 132M | 145M | 87M | 95M | 301M | 316.1M | |
| Reconciled Depreciation | 3.8B | 3.1B | 6.5B | 5.5B | 4.9B | 4.8B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AstraZeneca PLC shareholders. The income statement also shows AstraZeneca investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).